Tag Archives: Cancer

FED Publishing Releases New Book, “My Journey, A Victory Over Cancer Through Alternative Methods” by Valarie Hendriks

My Journey, A Victory Over Cancer Through Alternative Methods, by Valarie Hendriks, is a story about one courageous woman’s journey and victory over cancer through alternative methods.

Oakland Township, MI, USA — Valarie Hendriks’ My Journey, A Victory Over Cancer Through Alternative Methods is a book that will make you laugh, make you cry, inspire you and motivate you. However, most of all it will help you in battling one of the most dreaded diseases plaguing mankind, cancer.

Valarie Hendriks grew up in the Midwest part of the United States. After college she got a job in the Optical field and is currently working as a Manager and ABO Certified Optician. Along the way she got married to her spouse of twenty five years. Her hobbies are tennis, horseback riding and Ball Room Dancing. She competed in Ball Room Dancing and won several competitions over her career. Then one day she was diagnosed with cancer. At this point in her life she thought her entire world was falling apart. However, she was determined to defeat this dreaded disease.

Her book My Journey, A Victory Over Cancer Through Alternative Methods is a book that Valarie wrote that outlines how she beat cancer. In her book she provides all of the information that she learned through two years of research so that she could help other people in their battle against cancer without going through the trauma of traditional cancer treatments. Her book is uplifting, inspiring, and motivational. It will make you laugh and it will make you cry but most of all it could help you to defeat one of the most dreaded diseases in the world, the disease that we call cancer.

Genre – Cancer, Cure, Alternative Methods, Alternative Medicine, Cancer Cure, Inspiration, Treatment, Motivational

The ebook version of My Journey, A Victory Over Cancer Through Alternative Methods ISBN 9781506903477, published by First Edition Design Publishing (http://www.firsteditiondesignpublishing.com), is available on-line wherever ebooks are sold. The 194 page print book version, ISBN 9781506903460, and ISBN 9781506903453 hardback, are published by First Edition Design Publishing and distributed worldwide to online booksellers.

Media Contact:
Valarie Hendriks
+1(941)921-2607
monty-nbf@att.net

Immuno Biotech to present third paper on GcMAF at Immunotherapy and Immunomonitoring Conference

GcMAF helps body destroy cancer cells.

St Peter Port, Guernsey (March 4, 2013) — Immuno Biotech Ltd has been invited to present its latest research paper on GcMAF at the 3rd Immunotherapy and Immunomonitoring Conference on April 22-25, 2013 in Krakow, Poland. Entitled “The effects of Vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells,” it is about examining how GcMAF destroys breast and brain cancer cells by use of microscope photography and the fixing and staining of microscope slides. GcMAF is a key part of the human body’s immune system and the body’s own production is often reduced or prevented by diseases and cancer.

“This is the third scientific paper that we have presented in two months,” said David Noakes, the CEO of Immuno Biotech. “We are actively adding to the growing body of scientific papers being generated by leading scientists around the world who are investigating how GcMAF can help the body naturally fight off diseases and cancer. Currently there are over 59 research papers on GcMAF by 142 eminent scientists. This growing interest in GcMAF by the scientific community resulted in this invitation to present our latest scientific paper at this prestigious conference. Having positive peer reviews at these international conferences on the effects of GcMAF is stimulating more scientists to start looking at how GcMAF can help in their research into diseases and cancer.”

In the past two months, Immuno Biotech has presented at the International Cancer Conference in Dubai and, as a result, was asked to supply GcMAF for testing by the University of Sharjah on its library of 2,000 cancer cell lines. The same paper was also presented at the Immunology Conference in San Diego and was so well received that a number of scientists said that they would be now be re-directing their work. And at the International Dubai Autism Conference, their paper on GcMAF and autism, and the trial on 1,500 children with 15% of children making full recoveries, and 85% improving, resulted in Immuno Biotech being asked to supply GcMAF for similar large scale trials in Dubai.

“We are investing heavily in state-of-the-art research equipment and intend to produce several more papers by the end of the year,” added David Noakes. “For example, our new high powered microscopes have been able to video GcMAF being used to destroy cancer cells by activating the macrophages, which are the body’s own natural way of fighting invaders and cancer. We are the first to have videoed this and it really impresses the audiences at the conferences to see GcMAF actually in action.” Video at http://www.youtube.com/watch?v=D1WZrnCcH24&feature=player_embedded.

Immuno Biotech is organising the World’s first GcMAF Immunology Conference that will be held at the Holiday Inn Frankfurt, Germany on 19th, 20th and 21st of April. Registration is open now for doctors and research scientists at http://gcmafconference.org and, from March 20th, registration opens for members of the public and patients wishing to learn more about GcMAF.

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for scientists with the company being cited in over eight research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is continually produced by healthy humans and is a vital part of the body’s immune system. It directs the immune system to destroy foreign invaders, such as viruses and bacteria, as well as the body’s own cells when they turn cancerous. However, many diseases attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech extracts GcMAF molecules from healthy human blood. A weekly injection of a tiny clear drop restores the level of GcMAF to normal – effectively a millionth of a conventional transfusion. This enables the body’s own natural defence mechanisms to fight the infection with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. It is extremely safe as it is a naturally occurring blood product. Noticeable improvements usually happen within three weeks and the time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of chemotherapy, and, according to the research papers, more effective at fighting cancer. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Ph: 0044 7781 411737, Website: http://www.gcmaf.eu and click “contact” at the top to email.

Immuno Biotech presents GcMAF Research Papers on fighting Cancer and Autism treatment at International Conferences in the USA and Dubai

GcMAF helps fight Autism and Cancer by rebuilding body’s immune system.

Guernsey, UK (February 8, 2013) — On February 1, 2013, in simultaneous presentations at the Immunology Conference in San Diego, California and at the International Cancer Conference at the University of Sharjah in the United Arab Emirates, Guernsey-based company, Immuno Biotech Ltd. presented its latest research paper on GcMAF. The presentation was entitled “Multifaceted immunotherapeutic effects of GcMAF on human breast cancer cells.”

It included videos, taken through high powered microscopes in their laboratory, showing cancer cells being destroyed using GcMAF molecules, which they had extracted from human blood. GcMAF is a key part of the human body’s immune system and the body’s own production is often reduced as part of the attacking mechanism of diseases and cancer.

Lynda Thyer presented to an audience of over 200 American scientists at the Immunology Conference and was congratulated on the content by other scientists afterwards, in particular the videos which are a world first.

David Noakes, the CEO of Immuno Biotech, presented at the International Cancer Conference and was told afterwards that his presentation was the most easily understood in the three days of the conference. The University was sufficiently impressed to ask Immuno Biotech to provide GcMAF for use with the University’s huge library of 2,000 cancer cell lines, so that GcMAF can be tested with many more types of cancers in the laboratory. This will extend the knowledge of the effectiveness of GcMAF which has mainly been used in human trials so far. The University of Sharjah is one of the world leaders in cancer and molecular research, with state-of-the-art facilities attracting resident professors from all over the world.

David Noakes will also be presenting Immuno Biotech’s “GcMAF in Autism” research paper at the International Dubai Autism Conference, which was based on a US trial with 1500 autistic children. Most of them had significant reductions in autistic symptoms indicating that infection is playing a role in some forms of autism. The company has already been asked to supply GcMAF for three Dubai autism trials, on top of the 1,500 autistic children already treated. The conference will be held from February 6-9, 2013 at Zayed University, Dubai, bringing together international certified experts in the fields of behavioural therapy and special education.

There are 59 research papers by 142 eminent scientists on GcMAF, and Immuno Biotech Ltd are immensely proud to be adding their first two research papers to the list, with plans for lab experiments and human trial results data for at least another six papers this year.

David Noakes, Immuno Biotech’s CEO, said, “Isolating GcMAF is a complex process. Many scientists find it very challenging and time consuming and often fail to isolate it correctly and so they come to us as a source of consistent quality for their research. We have perfected our process in a state-of-the-art laboratory in the UK that isolates GcMAF from human blood and makes it available in a pure, sterile form to scientists, doctors, patients and researchers around the World. We are continually delighted by the flood of positive results in scientific papers that state GcMAF helps fight an increasingly wide range of diseases.”

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for scientists with the company being cited in over eight research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is continually produced by healthy humans and is a vital part of the body’s immune system. It directs the immune system to destroy foreign invaders, such as viruses and bacteria, as well as the body’s own cells when they turn cancerous. However, many diseases attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech has perfected the technique of extracting and isolating GcMAF molecules from healthy human blood. A weekly injection of a tiny clear drop restores the level of GcMAF in the blood to normal and enables the body’s own natural defence mechanisms to fight the infection with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. Noticeable improvements usually happen within three weeks and the time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of chemotherapy, and according to the research papers, more effective at fighting cancer. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781 411737, Web: http://gcmaf.eu and click “contact” at the top to email.

Trials Show Promise of Human Virus to Treat Head and Neck Cancer Patients

Cancers shrank for about one third of the patients who could be evaluated, and disease stabilised for a further third. For one patient, all signs of their cancer disappeared.

Leeds, UK – April 3, 2012 — A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published today in Clinical Cancer Research.

RT3D, trade name Reolysin, is a new drug developed by Oncolytics Biotech Inc with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. It is based on a virus (reovirus type 3 Dearing) that is found in almost all adults’ respiratory and gastrointestinal tracts without causing any symptoms.

RT3D has the ability to grow in and kill certain types of cancer cells, but does not grow in normal cells.

Previous trials injecting patients with the virus on its own showed limited effectiveness, but the team found that RT3D appeared to magnify the effects of platin and taxane-based chemotherapy on tumour cells.

Dr Kevin Harrington and colleagues in Leeds therefore started a clinical trial testing intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers who had stopped responding to standard treatments.

An initial Phase I study was carried out in patients with a range of advanced cancers, which showed the drug combination was safe. Side-effects were found to be generally mild, and consistent with chemotherapy alone.

Patients with head and neck cancers were found to have the best responses, so a Phase II expansion study at The Royal Marsden Hospital, London, and St James’s Hospital, Leeds, was therefore targeted to patients with these types of cancers.

Cancers shrank for about one third of the patients who could be evaluated, and disease stabilised for a further third. For one patient, all signs of their cancer disappeared.

“We saw really very impressive response rates in these patients. These are patients whose cancers had grown despite a great deal of previous treatment, including platinum-based chemotherapy for many,” Dr Harrington, Leader of the ICR’s Targeted Therapy Team and Consultant Oncologist at The Royal Marsden, said. “Under those circumstances, we’d expect that the average response rate to chemotherapy alone might be as low as single digits figures and the average survival would be somewhere between three to four months. In our Phase I/II study we show this had been prolonged to an average of seven months, albeit not in a randomised trial.”

“Based on the results of this study we’ve now started recruiting patients with advanced head and neck cancer to a randomised Phase III trial, in which all patients will receive chemotherapy and half will receive Reolysin as well. We are extremely excited about this progress.”

The study also found the virus was not shed after treatment. This means people could be given the drug as outpatients as no risk was found that they could transmit the virus to others.

Head and neck cancers include tumours of the eye, nasal cavity, tongue, gums, lip, cheeks, voice box and oesophagus. Around 650,000 people are diagnosed with squamous cell cancer of the head and neck each year worldwide, and around 350,000 die from the disease annually.

Notes to Editors:

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies with first author Eleni M. Karapanagiotou from the ICR and The Royal Marsden publishes in the print edition of Clinical Cancer Research on April 1.

The Phase III trial is recruiting patients with head and neck cancer who have already been treated with platinum but not taxane. More details at: http://clinicaltrials.gov/ct2/show/NCT01166542

The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes.

Scientists and clinicians at the ICR are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR’s mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 44,000 patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June 2010, along with the ICR, the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.

Since 2004, the hospital’s charity, The Royal Marsden Cancer Charity, has helped raise over £50 million to build theatres, diagnostic centres, and drug development units. Prince William became President of The Royal Marsden in 2007, following a long royal connection with the hospital.

Media Contacts:
Jane Bunce on 0207 153 5106 or after hours 077217 47900
Tatjana Trpoksa on 0207 153 5312 or after hours 07780689891

Media Contact (US) for Oncolytics: Janet Vasquez / 212-825-3210

On Friday September 30th MyDish.co.uk Will Be Turning To Its Baking Recipes In Support Of The Macmillan Cancer Support Event The ‘World’s Biggest Coffee Morning’

Macmillan Cancer Support is a charity close to MyDish.co.uk’s heart and as such is urging all to offer their support this coming Friday for the Macmillan ‘Coffee Morning’ event

Established in 1990, the Macmillan Cancer Support’s ‘Coffee Morning’ event quickly grew in popularity and soon became known as the ‘world’s largest coffee morning’. Last year alone saw 43,000 people get involved in this great cause helping to raise over eight million pounds.

Cancer is still a huge health risk for the UK population with statistics showing 1 in 3 people suffering from the illness at some point in their lives. These individuals require financial, emotional and medical support which Macmillan attempts to address and provide.

It is for this reason and many others that the founder of MyDish.co.uk, Carol Savage, is a big supporter of the charity and will be baking her favourite recipes for the Coffee Morning this coming Friday. Donning the chef’s hat and sourcing her favourite baking recipes, Carol will be baking her best cupcake recipes and selling them to support the Macmillan trust.

Asked about the Coffee Morning event Carol Savage said ‘Cancer is something that affects us all in some form or another.  My Mother-in law Maureen died of Leukeimia and she inspired me with her recipes to start MyDish.co.uk. Cancer is a very real illness that is just too common and we should do what we can to help and offer support .A few cupcakes here and there is not much to ask’

Making even the smallest donation can still make a big difference.  £25 alone can pay for the cost of a Macmillan nurse for an hour, helping to provide essential medical, practical and emotional support for cancer sufferers.

£51 can purchase a liquidiser for someone who can unfortunately no longer eat solid food as a result of their cancer treatment. These services and many like them are just some of the essentials cancer sufferers need and the Macmillan trust helps provide them.

If you need some recipe ideas this coming Friday then visit MyDish.co.uk.  Home to thousands of good recipes, MyDish.co.uk has hundreds of baking recipes and cupcake recipes ensuring that everyone can find the perfect baking recipe for the Coffee Morning .

You can add your own suggestions if you feel the MyDish.co.uk com munity would benefit. In addition to this you can also see loads of great recipes on MyDish that have been donated to Macmillan by big name celebrities. Check out Eva Longoria’s lovely Churros and Gwyneth Paltrow’s gorgeous Pancakes. Alternatively Judi Denchs’ delicious Rum and Chocolate Fudge may be more to your taste.

So this Friday spare a little extra change, get your baking gloves on, drink some coffee and join Carol Savage and www.mydish.co.uk in supporting this extremely worthwhile charity, as together we can make a difference.

###

 

Gene Therapy and Stem Cell Therapy Standard Developed For A Unique Derivative Of Post Hetero-Plastic Inplantation Chronic Inflammation Syndrome

Researchers task force, led by faculties of T-Protocol, registered Genom Project as controlled genom project in the hosted database of NCBI, a publication matter authority and function assigned organization under oversee of Department of Health & Human Services, reached once to share the exegetical impression officially pre-published concerning the understanding specific spectrum of symptoms covering boroad range of character usually complained and observed through chronic inflammation, granuloma, some types of lymphoma and various uncommon symptoms to let physician scientists suspecting indicium of neurological diseases, NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and setting Massachusetts indications of treatments standardized manual (Massachusetts manual) & diagnostic and standardized medical treatment manual for post hetero-plastic inplantation chronic inflammation syndrome, specific edition against NIDO Disease.

The once defined causes of NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome are considered each of a common living organism to cause conformational diseases like Creutzfeldt-Jakob disease, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and kinds of and a set of biochemical and physical reaction and response realized by cross-species gene- mutation, as biotransformation, easily describing natural physiological and biochemical changes in vivo substrate of human bodies. After this studies, standardized protocol of gene therapy and applied stem cell therapy is now in practice and on available.

Faculties,committing themselves entirely to the project, of each institutes and organizations participating the project to ascertain proteins and DNA/genomic DNA/genom of human, other mammal and virulent microorganism including bacillus/virus affecting each symptom and the symptoms’ spectrum expressed generally and observed commonly on patients suffered from NIDO disease, extraordinarily unique derived type of post hetero-plastic implantation chronic inflammation syndrome and to develop diagnostic standard and treatment protocol standardized and to find a clue compose gene therapy protocol and applied stem cell therapy protocol to entirely heal NIDO disease, an unique type of post hetero-plastic implantation chronic inflammation syndrome and to let all of current suffered patients from various combined symptoms directly derived by chronic inflammation and various tumors, have to express full surprise at the fact that these disease and patients suffered are made up and left no attention and no relief.

Commissioner of ethics board of the project will agree that this case should be regarded as not agreed human experimentation.

Contact Details: Genom Project Matter: http://www.ncbi.nlm.nih.gov
T-Protocol Treatment Matter: medinfo@vistomail.com
or near RMP accredited issuing referral

STEM 2011, the 7th Annual Conference on Biotechnology – to be held in Gurgaon (India) on 31st Jan & 1st Feb, 2011

* Focusing on latest trends in Stem Cells, Regenerative Medicine and Tissue Engineering.
* Stem Cell research a very frontline subject all over the world.
* Bringing advanced therapies based on the findings of scientists to the patients suffering from many incurable degenerative diseases.

Mumbai, India, January 04, 2011 — The 7th Annual Conference on Biotechnology, STEM 2011, organized by Society for Regenerative Medicine & Tissue Engineering (SRMTE), is being held in Gurgaon, India on 31st Jan & 1st Feb, 2011 at Club Patio (Unitech Patio) Block E, South City 1, Gurgaon, Haryana (India). The conference aims to increase awareness levels of the technical details in the field of stem cells, which is at an evolving stage.

STEM 2011 conference will bring together people working in the field of Stem Cell Research leading towards Stem Cell therapy and give ample scope to interact with leading personalities in this field. This field of research in stem cell biology would lead to possible treatment of presently incurable diseases like Spinal cord injury, Parkinson’s disease, Diabetes, Cancer, Generic diseases etc.

Stem Cell research is a very frontline subject at the moment all over the world. It is the core objective of SRMTE to bring together scientists and medical specialists engaged in the emerging area of medicine, namely regenerative medicine and tissue engineering and provide a common platform for these experts to share their findings and brainstorm on various issues connected with this field of specialization.

The two day conference will be attended by eminent speakers from Malaysia, Singapore, USA and within India and is ideal for Biotech and Pharma companies, Research Institutes, Hospitals, Doctors, Bioinformatics companies, Academics and Students.

Society for Regenerative Medicine & Tissue Engineering (SRMTE) ( http://www.srmte.org ) is a Non-Profit body in India formed in the year 2003 by a group of scientists working towards Stem Cell Research. For further details call + 91 9323275711 or log onto http://www.srmte.org.

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd
Mumbai, India 400 067
Tel: +91 22 2862 5131/ 32
Cell: +91 98205 03876
mitesh@publicrelaionindia.com, sangeeta@publicrelaionindia.com
http://www.srmte.org

UK Homes Are Second Largest Cause Of Lung Cancer

UK Homes And Showers Expose People To Cancer Causing Airborne Radon Gases. The World Health Organisation (WHO) Announced That The Second Biggest Cause Of Lung Cancer Is Through Low To Medium Exposure To Radon Gases In Homes.[1]

Smoking is the leading cause of lung cancer in the world. However, very few know that the second biggest cause of lung cancer is radon exposure in homes. Dr. Maria Neira of WHO (World Health Organisation): “Most radon-induced lung cancers occur from low and medium dose exposures in people’s homes. Radon is the second most important cause of lung cancer after smoking in many countries”.[1] In fact it accounts for 21,000 deaths a year (in America alone) for non-smokers. Conversely, second-hand smoke only accounts for 3,000 deaths per year. [2]

Radon is a naturally occurring radioactive gas borne out of the decay of uranium. Some might think that uranium is something that is only to be found in nuclear power stations, but in fact every square mile of the earth contains 1 gramme of uranium, which adds up to a lot of uranium and radon. Radon seeps into enclosed spaces like mines and also into underground water supplies where it is trapped within this water. A report released by the National Academy of Sciences states that there is a link between tap water and radon-induced lung cancer. [3]

One of the largest exposures to radon gases received daily is through inhalation of radon released from shower water. During showers radon particles are released as gases from hot water into the air as steam. The steam contains radon and within the confined space of showers and bathrooms, substantial amounts of radon gases are inhaled. The UK’s Health Protection Agency state that radon exposures in many homes are close to those received by uranium miners.[4]

The most effective and environmentally friendly way to protect against radon gases in the shower is to install a shower filter. Shower filters are easy-to-install shower heads that have an in-built water filter. As the radon particles pass through the filter, they are trapped and therefore make shower water free from radon. Shower filters have replaceable cartridges and also eliminate other impurities like; chlorine, magnesium, heavy metals, lime scale and other contaminants that can cause adverse health effects.

The UK’s Health Protection Agency provide radon test kits for homes and can be purchased by calling 01235 822 622.

Http://www.pureshowers.co.uk sells internationally tested and certified shower filters which remove radon. They can be purchased securely online at http://www.pureshowers.co.uk or by calling 0800 612 7174.

More information about radon in homes can be accessed on the UK’s Health Protection Agency’s website at:
http://www.hpa.org.uk/Topics/Radiation/Under...

 About The Company:

PureShowers.co.uk specialise in offering the latest technology in Shower Filters for health and beauty. The Http://www.pureshowers.co.uk filters are available online via a secure ecommerce store at http://www.pureshowers.co.uk

Prices start from £29.95 (including VAT) and can be ordered online or by calling 0800 612 7174.

What do its customers say?

Shirley Chan of London says: “I have been using the shower filter for three weeks now and I have noticed the difference in my skin and hair. Previously, my skin would feel very dry and itchy and I had to moisturise with an emollient cream, but now my skin feels soft and smooth and I no longer have to use my creams.”

Stephen Boyle of Essex says: “It’s easy to install. Well after two weeks since putting the filter on my shower, it’s great. I never realised how much damage chlorine does to the skin.”

Jacqueline Gallagher of Derry says:“The filter does everything it promised and I couldn’t be happier. I’ve recommended it to all my friends and am telling all my salon clients of the benefits.”

Notes to the Editor:

  • High Res. Images and Samples available on request
  • For further information, please contact: Ty Lee (media@pureshowers.com) or on TEL: +44 7805 777 762

———————————————
[1] Dr. Maria Neira of WHO (World Health Organisation): “Most radon-induced lung cancers occur from low and medium dose exposures in people’s homes. Radon is the second most important cause of lung cancer after smoking in many countries.” –http://www.epa.gov/radon/healthrisks.html

[2] http://www.epa.gov/radon/healthrisks.html

[3] http://www.epa.gov/radon/rnwater.html

[4] http://www.hpa.org.uk/Topics/Radiation/UnderstandingRad...